Clinical Lung Cancer

Aims & Scope

Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer.

Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer.

The main emphasis is on recent scientific developments in all areas related to lung cancer.

Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	3.3
2024	3.30

SJR (SCImago Journal Rank)

Year	Value
2024	1.515

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	78

Journal Rank

Year	Value
2024	2344

Journal Citation Indicator

Year	Value
2024	1660

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Exosomal MicroRNA: A Diagnostic Marker for Lung Cancer

  Citation: 1035

  Authors: Guilherme, Cicek, Jamie M., Douglas D., Goetz H.

• Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway

  Citation: 349

  Authors: Kim-Son H., Susumu, Daniel B.

• An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non–Small-Cell Lung Cancer

  Citation: 347

  Authors: Allison B., Suresh, David A., Marc, Yong Chan, Umberto, Maria T., Daniel R., Gavin M., Giulio, Michael T., Claudio V., Tommaso M., Dennis L., Andrew J., George B.

• Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas

  Citation: 244

  Authors: Ying, Jongphil, Yoganand, Qian, Alberto L., Olya, Zhaoxiang, Robert J.

• Emotional Problems, Quality of Life, and Symptom Burden in Patients With Lung Cancer

  Citation: 228

  Authors: Eleshia J., Paul J., Jeff A., Ping, Christi A., Kathryn J., Matthew M.

• Non–small-cell Lung Cancer With Brain Metastasis at Presentation

  Citation: 189

  Authors: Saiama N., Pamela P., Cliff G., Jeffrey, Siddhartha, Lingling, Ramaswamy, Feng, Varun, Daniel

• KRAS Mutations in Lung Cancer

  Citation: 186

  Authors: Niki, Clara, Carlota, Ignacio, Ana, Miguel Angel, Rafael

• Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

  Citation: 181

  Authors: Martin E., Kelly, Richard B., Edward J., Stanley M., Ruth, Tommy, Srikesh, Sukhi, Harry, Andrew L., Eric V., Stuart L.

• K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review

  Citation: 175

  Authors: Sarit, Fiona H., Frances A., Ming-Sound

• Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer

  Citation: 168

  Authors: Mathieu, Pascale, Solene, Arnaud, Maxime, Nataliya, Julien, Youssef, Laurent, Marilyne, Mohamed, Celine, Fabrice

---